News
US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...
MapLight Therapeutics initiates phase 2 ZEPHYR study of M1/M4 muscarinic agonist ML-007C-MA to treat schizophrenia: Redwood City Thursday, July 10, 2025, 13:30 Hrs [IST] MapLight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback